BIOGEN INC. - COMMON S

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

10 7 2025 06:00:00 提供 Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

30 6 2025 06:30:12 提供 Nasdaq GlobeNewswire

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

27 6 2025 09:00:23 提供 Nasdaq GlobeNewswire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

25 6 2025 06:30:37 提供 Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

18 6 2025 06:30:27 提供 Nasdaq GlobeNewswire

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

12 6 2025 00:00:39 提供 Nasdaq GlobeNewswire

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

27 5 2025 06:30:00 提供 Nasdaq GlobeNewswire

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

15 4 2025 18:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

09 4 2025 08:45:15 提供 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

08 4 2025 12:06:04 提供 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

07 4 2025 08:45:03 提供 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

04 4 2025 08:47:36 提供 NetDania Notify

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

02 4 2025 06:30:00 提供 Nasdaq GlobeNewswire

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

24 3 2025 06:30:00 提供 Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

11 3 2025 06:30:00 提供 Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

18 2 2025 07:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

12 2 2025 08:45:10 提供 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

11 2 2025 10:11:08 提供 NetDania Notify

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

31 1 2025 05:30:52 提供 Nasdaq GlobeNewswire

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

26 1 2025 17:33:52 提供 Nasdaq GlobeNewswire